ECM
SABS icon

Elgethun Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Elgethun Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-544
Closed -$6.47K – 157
2023
Q4 		$6.47K Sell
544
-450
-45% -$3.77K ﹤0.01% 153
2023
Q3 		$6.36K Hold
994
– – ﹤0.01% 157
2023
Q2 		$8.25K Buy
994
+290
+41% +$2.38K ﹤0.01% 157
2023
Q1 		$3.22K Sell
704
-776
-52% -$4.91K ﹤0.01% 130
2022
Q4 		$9.17K Buy
1,480
+150
+11% +$1.37K ﹤0.01% 124
2022
Q3 		$9K Hold
1,330
– – ﹤0.01% 119
2022
Q2 		$18K Buy
+1,330
New +$27.9K 0.01% 116

Other funds holding SABS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Elgethun Capital Management's SABS Position: Q1 2024 in Review

Elgethun Capital Management sold out of SAB Biotherapeutics (SABS) in Q1 2024, closing a stake of 544 shares — an estimated $6.47K sold.

Elgethun Capital Management first reported a position in SABS in Q2 2022 and held it in 7 quarters. The position peaked at $18K in Q2 2022. 24 funds tracked by Wall St. Rank hold SABS as of Q1 2024.

  • Elgethun Capital Management reported no remaining SAB Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Elgethun Capital Management sold 544 SAB Biotherapeutics shares in Q1 2024, an estimated $6.47K.
  • Elgethun Capital Management first reported a position in SAB Biotherapeutics in Q2 2022 and held it in 7 quarters.
  • Elgethun Capital Management's SAB Biotherapeutics position peaked at $18K in Q2 2022.
  • 24 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2024.

Based on Elgethun Capital Management's 13F filing for Q1 2024, filed 14 May 2024.